

# Disease modulation of GPCR oligomer expression in the brain





[www.ub.edu/neuropharmpain](http://www.ub.edu/neuropharmpain)

# Outline


- 1. Introduction: G protein-coupled receptors oligomerization**
- 2. Visualizing adenosine/dopamine receptors oligomers in native tissue (i.e. striatum)**
- 3. Potential impact of adenosine and dopamine receptors oligomerization in Parkinson's disease therapeutics**
- 4. Overall conclusion**

# General principle of the GPCR signalling system




Vilardaga et al., 2010. J. Cell. Sci. 123, 4215-4220.

# GPCR oligomerization



# Question

There is any relationship between Parkinson's disease and A<sub>2A</sub>R/D<sub>2</sub>R oligomerization state?




## Basal ganglia circuitry and PD







Vallano et al., 2013. CNS & Neurol. Dis.-Drug Targets. 12(8):1128-42.

# Detection of striatal A<sub>2A</sub>R/D<sub>2</sub>R oligomer in a PD animal model

The 6-OHDA-lesioned rat:  
a validated animal model of PD



# $D_2R$ - $A_{2A}R$ co-clustering in the striatum of normal and 6-OHDA-lesioned rats




Fernández-Dueñas *et al.* (2015). Dis Model Mech. 8(1):57-63.


**2. Oligomerization in native tissue**

# The PLA technique


A. Immunodetection




B. PLA probes binding



C. Annealing & Ligation




D. RCA & Detection



Taura *et al.* (2015). Current Protocols in Cell Biology **67**, 17.17.1-17.17.16.

**2. Oligomerization in native tissue**

# Detection of D<sub>2</sub>R and A<sub>2A</sub>R proximity in normal and 6-OHDA-lesioned rat striatal sections




Fernández-Dueñas *et al.* (2015). Dis Model Mech. 8(1):57-63.

## 2. Oligomerization in native tissue









# Detection of D<sub>2</sub>R and A<sub>2A</sub>R proximity in normal and 6-OHDA-lesioned rat striatal sections

TR-FRET using fluorescent adenosine and dopamine receptor antagonists in striatal membranes





# Detection of adenosine receptor containing oligomers in HEK cells



Fernández-Dueñas *et al.* (2015). Dis Model Mech. 8(1):57-63.

## 2. Oligomerization in native tissue


# Detection of adenosine receptor containing oligomers in native tissue



Fernández-Dueñas *et al.* (2015). Dis Model Mech. 8(1):57-63.

## 2. Oligomerization in native tissue



# Detection of the A<sub>2A</sub>R/D<sub>2</sub>R oligomer in the striatum of the PD animal model



Fernández-Dueñas *et al.* (2015). Dis Model Mech. 8(1):57-63.

# Conclusion



$A_{2A}R/D_2R$  oligomer is unbalanced in experimental parkinsonism




# Functional impact of oligomer down-regulation

## The striatal A<sub>2A</sub>R shows constitutive activity in experimental parkinsonism

- Caffeine-evoked locomotor activity in 6-OHDA lesioned mice




- cAMP measurement in striatal synaptosomes






Fernández-Dueñas *et al.* (2014). ACS Chem. Biol. 9 (11), 2496-2501.

# Which should be the profile of an anti-PD drug?



# Effect of D<sub>2</sub>R challenge on real-time A<sub>2A</sub>R agonist binding



Fernández-Dueñas et al., 2012. J. Neurochem. 123, 373-384.

3. Oligomer-dependent allosterism

# **Effect of D<sub>2</sub>R challenge on real-time A<sub>2A</sub>R agonist binding**

**D<sub>2</sub>R agonists are negative allosteric modulators (NAMs) of A<sub>2A</sub>R binding and this phenomenon is A<sub>2A</sub>R/D<sub>2</sub>R oligomer dependent**

**Parkinson's disease context**

# Effect of D<sub>2</sub>R challenge on real-time A<sub>2A</sub>R agonist binding

Screening for more efficacious D<sub>2</sub>R agonists to be used in PD management

Discontinued

Bromocriptine

Lisuride

Pergolide

Piribedil



Pramipexole

Ropinirole

Rotigotine

# Effect of D<sub>2</sub>R challenge on real-time A<sub>2A</sub>R agonist binding


Testing the A<sub>2A</sub>R NAM activity of most common therapeutic D<sub>2</sub>R agonists



Fernández-Dueñas *et al.* (2013). Neurochem. Int. 63 (1), 42-46.

# Conclusion

## Ontogeny of A<sub>2A</sub>R/D<sub>2</sub>R oligomer in normal and pathological conditions



# Overall Conclusion

- ✓ We demonstrate the existence of the  $A_{2A}R/D_2R$  oligomers in native tissue (i.e. striatum)
- ✓ The striatal dopaminergic denervation induces a down-regulation of the  $A_{2A}R/D_2R$  oligomer
- ✓ The down-regulation of the striatal  $A_{2A}R/D_2R$  oligomer correlates well with an increase in  $A_{2A}R$  constitutive activity
- ✓  $D_2R$  agonists behave as  $A_{2A}R$  NAMs in an oligomer-dependent manner. Thus, this might be interesting in the design, screening and usage of  $D_2R$ -based drugs for PD pharmacotherapy

# Thanks to our collaborators!

Kathleen Van Craenenbroeck

Ghent University, Belgium

Rodrigo Cunha

Unv. Coimbra, Portugal

Isidre Ferrer

IDIBELL, Spain

Thierry Durroux & Jean-Philippe Pin

IGF, France

Ken Jacobson

NIH, USA

Veli-Pekka Jaakola

Oulu University, Finland

Kjell Fuxe

Karolinska Institutet, Sweeden

Igor Stagljar

Toronto University, Canada

JM Arnau

A Vallano

C Pedrós

S Sánchez

L Cuffí

L Carbonell

V Fernández

X Morató

J Taura

M Gómez

M López

G García

M Valle

S Sánchez



Rafael Luján

Unv. Castilla-La Mancha, Spain

Carla Tasca

UFSC, Brasil

Paul Slesinger

Mount Sinai, USA

Jean-Pierre Vilardaga

University of Pittsburgh, USA

Masahiko Watanabe

Hokkaido University School of Medicine, Japan



PCIN-2013-019-C03-03

